In January 2012, the UK Medicines and Health Products Administration (MHRA) issued an EU-GMP certification to Sichuan Xieli Pharmaceutical Co., Ltd., which is valid in 25 EU countries.

　　In August 2011, the GMP inspector of MHRA conducted an EU GMP on-site audit and inspection of three API products of Xieli Pharmaceutical, and affirmed the GMP production management level of Xieli Pharmaceutical products.

　　At present, a few enterprises in China have passed the GMP certification of the European Union. Through EU-GMP certification, it means that pharmaceutical companies have a "green pass" for their related raw material drug products to enter the international market, and also marks that domestic pharmaceutical companies have entered the ranks of international GMP pharmaceutical companies. Xieli Pharmaceutical is a GMP pharmaceutical enterprise that produces plant-based export raw material drugs, specializing in plant planting, natural active ingredient extraction and derivative synthesis research, anti-tumor series, and drug formulation production.

　　Drug Safety Supervision Department of Provincial Bureau